As recently as 15 years ago, acute ischemic stroke patients had few treatment options. The arrival of the pioneering—and at the time, controversial—MERCI Retrieval System on the US market in 2004 served to transform the treatment paradigm for this devastating and costly condition by offering physicians and patients a long-awaited fast-acting, life-saving intervention.
“When One Door Closes Another Door Opens: The Story of Telluride Medical Partners.” Emerging Arizona-based medical device accelerator Telluride Medical Partners LLC (TMP) is comprised of business entrepreneurs, medical device start-up experts, and medtech engineers who are committed to bringing disruptive technologies to market. In this candid interview, Founder and CEO Eric Wells talks about his early career, his experiences in founding the company, and what’s next for TMP.
In this new installment of his series of interviews on corporate governance in medtech, DeNovo Ventures’ Managing Director Joe Mandato speaks with Jay Watkins, also a Managing Director at De Novo Ventures and at Curation Capital. Jay has served in multiple board roles and shares his insights on what makes a good board tick.
Competitors in the diabetes market are working to meet consumer demand for more digitally integrated and interconnected diabetes management solutions, and collaborations among the various participants represent the new norm in this industry. In this ICYMI, Big pharma Eli Lilly partners with medtech to shift its diabetes focus from molecules to outcomes.
“Sana’s Wearable Solution for Chronic Pain” Boulder, CO-based start-up Sana Health is taking on one of the biggest health crises in the world today: opioid use, as part of a larger mission to redefine the way pain is treated. Sana’s novel FlowState technology induces deep relaxation, promotes neuroplasticity, reduces pain, and triggers sleep in as little as 10 minutes. In this interview, Founder Richard Hanbury talks about his experiences in founding the company and what’s next for Sana Health.
As noted in previous posts here on the Community Blog, dialysis is a therapy whose time has come, and disruptive innovation is needed. In a first-of-its-kind partnership between the US Department of Health and Human Services and the American Society of Nephrology, the ongoing KidneyX: Redesign Dialysis prize competition is looking to spur medtech innovation that completely disrupts the way kidney failure is treated.
Driven by his passion to take care of the people who willingly put their lives on the line, Medical Technology Enterprise Consortium’s COO, William Howell, talks to the Community Blog about the goals of MTEC, and cutting-edge biomedical research that has recently received funding through this US Army organization. Although research is primarily focused on restoring function to severely injured soldiers, many of the medical technologies originally developed by or with funding support from the US military are also impacting the lives of millions of civilian patients.
“Billy Cohn, MD: Making Medtech Makers at Johnson & Johnson’s CDI @TMC” In this candid video interview onsite at the Center for Device Innovation in Houston, TX, Billy Cohn, MD, VP of Johnson & Johnson’s Medical Device Companies and Director, CDI @ TMC reflects on his extensive device patent journey and shares the keys to overcoming the never-ending challenges that plague device innovation.
As the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) describes it, vascular access is so important to a hemodialysis patient that it can be considered a ‘lifeline.’ However, this vital access site is prone to stenosis, thrombosis, and costly re-interventions. Laminate Medical Technologies hopes to support this critical lifeline with a first-of-its-kind external support device for AV fistulas, that alleviates wall tension and regulates an undesired narrowing of the vein and/or frequent blockages of the blood vessels.
End-stage renal disease treatment is a little known but dominant cost driver for the global healthcare system, and the number of patients needing regular dialysis in order to stay alive—and repeated interventions to combat complications—is growing. With its origins as a blood-filtering machine devised from tin cans, sausage casings and other non-medical parts by a determined Dutch physician in World War II Netherlands, today medical device companies such as Healionics are working to address the most critical and costly unmet need in dialysis: maintaining healthy and functional access to the bloodstream.
There are about 466 million people worldwide with disabling hearing loss, 48 million of them in the US. To date, hearing aid devices have been the only solution to sensorineural hearing loss, the kind that comes from aging and the damage loud sounds cause. Eyeing the potential blockbuster opportunity, pharmaceutical companies like Decibel Therapeutics have finally joined the fray.
Robotics were the hot topic at NASS 2018, but discussions also raged about advanced implant materials that have the potential to promote better bone growth and faster healing and reduce reliance on expensive biologics to achieve those goals. An excerpt from Senior Writer Wendy Diller’s November 16 feature, “At NASS 2018, Advanced Biomaterials and the Pull of Robots.”
PAH, a progressive, incurable disease leading to right heart failure that strikes mostly women in the prime of life, has limited treatment options beyond some of the most expensive drugs covered by Medicare. TCT 2018 Shark Tank winner Aria CV hopes to impact the poor prognosis for this disease by focusing its first-of-a-kind, fully implantable device on a fundamental new mechanism of action—mimicking the function of a healthy pulmonary artery.